“The existing circumstance has uncovered some structural weaknesses from the EU’s medicines offer chain plus a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She advisable that offer chain difficulties be resolved in an EU pharmaceutical strategy expected being launched by the tip with th